Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature

  • Authors:
    • Angeliki Andrikopoulou
    • Kristiana Goga
    • Katerina Stefanaki
    • Stavroula A. Paschou
    • Stavros Athanasopoulos
    • Flora Zagouri
    • Meletios-Athanasios Dimopoulos
  • View Affiliations

  • Published online on: July 1, 2024     https://doi.org/10.3892/ol.2024.14550
  • Article Number: 417
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cushing's syndrome (CS), as a result of ectopic adrenocorticotropic hormone (ACTH) production, constitutes a common paraneoplastic manifestation of various malignancies, with the most common being small cell lung carcinoma. In the literature, fewer than fifty cases associating ectopic CS with prostate cancer have been documented. In the present study, the case of a 76‑year old man suffering from castration‑resistant prostate adenocarcinoma that had been treated with enzalutamide and luteinizing hormone‑releasing hormone (LHRH) analogue for the last four years is presented. The patient presented to the emergency department with lower extremity muscle weakness, bradypsychia and hypokalemia. Following a thorough diagnostic evaluation, hypercortisolemia was identified. No suppression after low‑ and high‑dose dexamethasone challenge, increased cortisol 24 h excretion and normal pituitary magnetic resonance imaging led to the diagnosis of ectopic CS. Immediate targeted therapy was initiated with adrenal steroidogenesis inhibitors, including metyrapone and ketoconazole along with chemotherapy with docetaxel and prednisolone. There was a remarkable decrease in cortisol levels within days and hospitalization was no longer required. The patient managed to complete three cycles of chemotherapy; unfortunately, he succumbed within three months of the diagnosis of ectopic CS. In the present study, all existing cases of paraneoplastic CS related to prostate cancer are reviewed. The aim of the current study was to highlight the need of early diagnosis and treatment of this entity as it may present with atypical clinical findings and potentially evolve to a life‑threatening condition.
View Figures
View References

Related Articles

Journal Cover

September-2024
Volume 28 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Andrikopoulou A, Goga K, Stefanaki K, Paschou SA, Athanasopoulos S, Zagouri F and Dimopoulos M: Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature. Oncol Lett 28: 417, 2024.
APA
Andrikopoulou, A., Goga, K., Stefanaki, K., Paschou, S.A., Athanasopoulos, S., Zagouri, F., & Dimopoulos, M. (2024). Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature. Oncology Letters, 28, 417. https://doi.org/10.3892/ol.2024.14550
MLA
Andrikopoulou, A., Goga, K., Stefanaki, K., Paschou, S. A., Athanasopoulos, S., Zagouri, F., Dimopoulos, M."Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature". Oncology Letters 28.3 (2024): 417.
Chicago
Andrikopoulou, A., Goga, K., Stefanaki, K., Paschou, S. A., Athanasopoulos, S., Zagouri, F., Dimopoulos, M."Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature". Oncology Letters 28, no. 3 (2024): 417. https://doi.org/10.3892/ol.2024.14550